CSL shares: Buy, sell or hold in 2025?

Three investment experts offer their view on the outlook for CSL shares.

| More on:
Buy, hold, and sell ratings written on signs on a wooden pole.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are up 0.3% at $261.87 today, shaking off the broader market sell-down. 

This sees the company with a market cap of almost $127 billion, making it the third largest stock on the ASX.

Over the past year, however, shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock have trailed the benchmark, sliding 9%, while the ASX 200 has gained 8%.

Though those losses were somewhat moderated by the $4.25 a share in unfranked dividends CSL paid out (or shortly will pay out) over the year.

But with CSL shares continuing to struggle in 2025, is the biotech stock one to buy, sell, or hold onto?

Below, we look at the investment case for each option (courtesy of The Bull).

Time to sell CSL shares?

If you ask three different analysts what their outlook is for CSL shares, you may well get three different replies.

With that in mind, Daylight Financial Group's Elio D'Amato has a rather bearish outlook on the stock.

"The biotechnology giant disappointed the market with its first half result in fiscal year 2025," said D'Amato, who has a sell recommendation on CSL stock.

D'Amato noted:

Revenue at the company's vaccine division Seqirus was down 9% due to low immunisation rates, particularly in the US. The plasma collection division CSL Behring remains the key profit driver.

The company is expected to meet full year net profit after tax and amortisation of $3.2 billion to $3.3 billion at constant currency.

Addressing the dawdling share price, D'Amato concluded:

With limited near-term catalysts amid concerns about the outlook for Seqirus, some investors may see better opportunities elsewhere, particularly as the share price has done nothing for years.

Know when to hold 'em

Medallion Financial Group's Stuart Bromley has a more optimistic take on CSL shares.

"The share price of this global healthcare powerhouse was recently punished after posting what investors considered was an underwhelming interim result in fiscal year 2025," said Bromley, who has a hold recommendation on the stock.

Noting that he's "encouraged by CSL's longer-term prospects", Bromley added:

The plasma business Behring performed well and is positioned for growth after rolling out 220 new collection centres. The vaccines business in the first half was weak, but we expect a stronger second half as Northern Hemisphere revenues flow to the business.

The bullish case for CSL shares

Family Financial Solutions' Jabin Hallihan believes the retrace in CSL shares makes the ASX 200 biotech stock attractive at current levels.

"The company's share price recently hit a 52-week low, making it an attractive entry point, in our view," said Hallihan, who has a buy recommendation on the stock.

According to Hallihan:

Despite mixed half year results in fiscal year 2025, the company lifted net profit after tax by 7% at constant currency. A strong performance from CSL Behring amid a dividend increase in Australian currency of 16% on the prior corresponding period highlight its potential.

The company is positioned to deliver annualised double-digit earnings growth in the medium term.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »